{
  "docId": "019de074-559c-76fa-9457-a7d91e9a06c5",
  "docSlug": "15199f0b497c4ef204a0760da27401b3",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 54 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2938006,
  "pageNumber": 14,
  "pageCount": 54,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 8,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-559c-76fa-9457-a7d91e9a06c5/14",
  "deckHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5",
  "deckJsonHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5.json",
  "deckAnchorHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.05,
        "y": 0.315
      },
      "kind": "paragraph",
      "text": "3Q-2022 Snapshot: Cash and equivalents 9/30/22: $40.4 M, Common shares o/s (11/9/22): 84.8 M, Warrants o/s: 1.4 M",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16d23cfe-6ef7-481f-bcbe-0c90c8311df9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.5,
        "x": 0.45,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "Non-dilutive Cash received: 3Q-2022: ~$18.0 M, Upfront license fee from Organon $10.0 M, Existing grant for DARE-LARC1: ~$8.0 M, October 2022: Cash rebate, AU R&D program ($US) : ~$786,000, November 2022: Grant to develop novel hydrogel formulation for delivery of live biotherapeutics to support vaginal health: $584,986, December 2022: Existing grant for DARE-LARC1: ~$4.4 M",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88d30042-30a8-4ef3-b1bb-73247d6fac92",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.6
      },
      "kind": "paragraph",
      "text": "Funding sources: Since inception, we have raised cash through sale of equity securities, M&A transactions, warrant and option exercises, non-dilutive grants, and license fees. We endeavor to be creative and opportunistic in seeking capital required to advance our candidates, and to be efficient in use of such capital",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a9526eba-ecdb-4cab-b9ad-75e647bb241c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.3,
        "x": 0.03,
        "y": 0.17
      },
      "kind": "title",
      "text": "Daré Financial Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f58afcd7-74de-4f12-a9f3-40f55772f7e4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}